Net Zero Focus Chiesi UK emphasizes sustainability with a B Corp certification and a plan to achieve Net Zero by 2035, presenting opportunities to discuss environmental monitoring solutions, sustainable packaging, and ESG-aligned partnerships with healthcare customers and NHS suppliers.

Respiratory and Rare Diseases The portfolio focus on respiratory health, rare diseases, and specialty care suggests potential sales use cases for targeted diagnostics, patient support programs, and digital health tools that improve adherence and outcomes in these patient segments.

NHS Collaboration Close collaboration with the NHS and UK Ireland healthcare organizations signals opportunities to offer integrated care solutions, value-based procurement strategies, and real-world evidence initiatives that demonstrate patient outcomes.

High Growth, Medium Scale With a UK team around 400 and revenue in the tens of millions globally, there is room to scale pilot programs, expand field-based engagement, and pilot new therapies or services in the UK market while leveraging their status as an outstanding employer for talent-enabled projects.

Global Connectivity As a long-standing biopharma player operating across 100 countries, Chiesi UK can serve as a gateway for international partners, cross-border distribution, and shared R&D or digital health initiatives that align with multinational pharma strategies.